Merck KGaA Full Year 2023 Earnings: In Line With Expectations
Merck KGaA (ETR:MRK) Full Year 2023 Results
Key Financial Results
Revenue: €21.0b (down 5.6% from FY 2022).
Net income: €2.82b (down 15% from FY 2022).
Profit margin: 14% (down from 15% in FY 2022). The decrease in margin was driven by lower revenue.
EPS: €6.50 (down from €7.65 in FY 2022).
MRK Products In Clinical Trials
Phase I: 5.
Phase II: 5.
Phase III: 4.
MRK Post-Clinical Trial Products
Pre-registration: 1.
Approved (during full year): 1.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Merck KGaA Meets Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations.
The primary driver behind last 12 months revenue was the Life Science segment contributing a total revenue of €9.36b (45% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to €4.51b (47% of total expenses). Explore how MRK's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Pharmaceuticals industry in Germany.
Performance of the German Pharmaceuticals industry.
The company's share price is broadly unchanged from a week ago.
Balance Sheet Analysis
Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. See our latest analysis on Merck KGaA's balance sheet health.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
